Royalty Pharma plc Dividends, Cash
Royalty Pharma plc (RPRX) reported Dividends, Cash of $104.92 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:DividendsCash · last filed 2026-08-05
- Royalty Pharma plc dividends, cash for the quarter ending 2026-06-30 was $104.92M, a 12.44% increase year-over-year.
- Royalty Pharma plc dividends, cash for the quarter ending 2026-03-31 was $104.49M, a 9.58% increase year-over-year.
- Royalty Pharma plc dividends, cash for the quarter ending 2025-12-31 was $94.34M, a 0.73% increase year-over-year.
- Royalty Pharma plc dividends, cash for the quarter ending 2025-09-30 was $95.31M, a 1.32% increase year-over-year.
- Royalty Pharma plc dividends, cash for fiscal 2025 was $378.32M, a 0.49% increase from fiscal 2024.
- Royalty Pharma plc dividends, cash for fiscal 2024 was $376.46M, a 5.06% increase from fiscal 2023.
- Royalty Pharma plc dividends, cash for fiscal 2023 was $358.33M, a 7.50% increase from fiscal 2022.
- Royalty Pharma plc dividends, cash for fiscal 2022 was $333.32M, a 16.88% increase from fiscal 2021.
| Period end | Dividends, Cash 3 month | Dividends, Cash 6 month | Dividends, Cash 9 month | Dividends, Cash 12 month |
|---|---|---|---|---|
| 2026-06-30 | $104.92M 10-Q · filed 2026-08-05 | $209.41M 10-Q · filed 2026-08-05 | $303.75M derived: sum of 3 quarters · filed 2026-08-05 | $399.06M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $104.49M 10-Q · filed 2026-05-06 | $198.83M derived: sum of 2 quarters · filed 2026-05-06 | $294.14M derived: sum of 3 quarters · filed 2026-05-06 | $387.45M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $94.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $189.65M derived: sum of 2 quarters · filed 2026-02-11 | $282.96M derived: sum of 3 quarters · filed 2026-08-05 | $378.32M 10-K · filed 2026-02-11 |
| 2025-09-30 | $95.31M 10-Q · filed 2025-11-05 | $188.62M derived: sum of 2 quarters · filed 2026-08-05 | $283.97M 10-Q · filed 2025-11-05 | $377.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $93.31M 10-Q · filed 2026-08-05 | $188.67M 10-Q · filed 2026-08-05 | $282.32M derived: sum of 3 quarters · filed 2026-08-05 | $376.38M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $95.36M 10-Q · filed 2026-05-06 | $189.01M derived: sum of 2 quarters · filed 2026-05-06 | $283.07M derived: sum of 3 quarters · filed 2026-05-06 | $378.02M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $93.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $187.72M derived: sum of 2 quarters · filed 2026-02-11 | $282.66M derived: sum of 3 quarters · filed 2026-02-11 | $376.46M 10-K · filed 2026-02-11 |
| 2024-09-30 | $94.06M 10-Q · filed 2025-11-05 | $189.00M derived: sum of 2 quarters · filed 2025-11-05 | $282.81M 10-Q · filed 2025-11-05 | $372.15M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $94.94M 10-Q · filed 2025-08-06 | $188.75M 10-Q · filed 2025-08-06 | $278.09M derived: sum of 3 quarters · filed 2026-02-11 | $367.84M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $93.81M 10-Q · filed 2025-05-08 | $183.14M derived: sum of 2 quarters · filed 2026-02-11 | $272.89M derived: sum of 3 quarters · filed 2026-02-11 | $363.50M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $89.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $179.09M derived: sum of 2 quarters · filed 2026-02-11 | $269.69M derived: sum of 3 quarters · filed 2026-02-11 | $358.33M 10-K · filed 2026-02-11 |
| 2023-09-30 | $89.75M 10-Q · filed 2024-11-06 | $180.36M derived: sum of 2 quarters · filed 2024-11-06 | $268.99M 10-Q · filed 2024-11-06 | $353.19M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $90.61M 10-Q · filed 2024-08-08 | $179.24M 10-Q · filed 2024-08-08 | $263.44M derived: sum of 3 quarters · filed 2025-02-12 | $347.25M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $88.63M 10-Q · filed 2024-05-09 | $172.83M derived: sum of 2 quarters · filed 2025-02-12 | $256.64M derived: sum of 3 quarters · filed 2025-02-12 | $339.69M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $84.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $168.01M derived: sum of 2 quarters · filed 2025-02-12 | $251.06M derived: sum of 3 quarters · filed 2025-02-12 | $333.32M 10-K · filed 2025-02-12 |
| 2022-09-30 | $83.81M 10-Q · filed 2023-11-08 | $166.86M derived: sum of 2 quarters · filed 2023-11-08 | $249.12M 10-Q · filed 2023-11-08 | $322.72M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $83.05M 10-Q · filed 2023-08-08 | $165.31M 10-Q · filed 2023-08-08 | $238.91M derived: sum of 3 quarters · filed 2024-02-15 | $311.93M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $82.26M 10-Q · filed 2023-05-09 | $155.87M derived: sum of 2 quarters · filed 2024-02-15 | $228.88M derived: sum of 3 quarters · filed 2024-02-15 | $301.46M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | $73.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $146.62M derived: sum of 2 quarters · filed 2024-02-15 | $219.20M derived: sum of 3 quarters · filed 2024-02-15 | $285.18M 10-K · filed 2024-02-15 |
| 2021-09-30 | $73.02M 10-Q · filed 2022-11-08 | $145.60M derived: sum of 2 quarters · filed 2022-11-08 | $211.58M 10-Q · filed 2022-11-08 | $269.19M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $72.58M 10-Q · filed 2022-08-04 | $138.56M 10-Q · filed 2022-08-04 | $196.17M derived: sum of 3 quarters · filed 2023-02-15 | $251.05M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $65.98M 10-Q · filed 2022-05-05 | $123.59M derived: sum of 2 quarters · filed 2023-02-15 | $178.47M derived: sum of 3 quarters · filed 2023-02-15 | |
| 2020-12-31 | $57.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $112.49M derived: sum of 2 quarters · filed 2023-02-15 | $112.49M 10-K · filed 2023-02-15 | |
| 2020-09-30 | $54.88M 10-Q · filed 2021-11-10 | $54.88M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |